Skip to content

Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health

Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.
Read more
image that reads: Introduction: 1/4/6 x24 - a campaign to rally energy, political will & funding to end TB

1/4/6×24 Community Campaign Training Materials

Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…

Read more

Storytelling to Support TB Preventive Treatment (TPT)

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…

Read more

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission,  mdc-STM currently in preclinical stage, and developed by MedinCell.
Read more
Back To Top